GE HealthCare Technologies Inc.

- No explicit mention of new fundraising through debt or equity in the provided transcript. - The company completed the Intelerad acquisition and repaid $500 million of debt in the first quarter. - They executed a balanced capital allocation strategy including share repurchases (~$100 million) and dividends. - Free cash flow generation continues strong ($112 million in Q1), supporting organic investments and disciplined M&A. - Management emphasized investing organically and disciplined M&A rather than indicating plans for new debt or equity issuance. - No specific comments on planned future debt or equity fundraising, suggesting current capital deployment is funded through cash flow and existing resources.

- The company plans to continue investing organically in the business, with an emphasis on R&D to drive future growth (Page 13). - They maintain appropriate investment levels to support innovation and pipeline progress, ensuring the business moves forward (Page 13). - Disciplined M&A is part of their capital deployment strategy, exemplified by the recent Intelerad acquisition to enhance cloud capabilities and outpatient networks (Pages 10, 13). - Capital deployment is balanced between organic investment, strategic acquisitions, and opportunistic share buybacks when valuations are favorable (Page 13). - No specific new large capital expenditure projects were detailed, but emphasis is on supporting innovation like Photon Counting CT and MR advancements with AI-powered solutions contributing to future revenue growth starting 2027 (Pages 2, 10). - The company is managing inflationary pressures with price and cost actions to protect margins while continuing strategic investments (Pages 4, 10, 13).

- Company maintains top-line guidance of 3% to 4% organic sales growth for 2026, reflecting healthy global customer demand and a good start to the year. - Strong momentum in new product innovations expected to drive more meaningful revenue starting in 2027, especially from Precision Care pipeline in CT and MR modalities. - Radiopharmaceutical portfolio growing well, with Flyrcado doses increasing nearly 80% since late January and a medium-term target of $500 million+ annual revenue by 2028. - Capital equipment market remains healthy with robust order growth and record backlog supporting revenue acceleration in the second half of the year. - Intelerad acquisition expands cloud capabilities and is expected to accelerate sales growth beyond 2026. - New anesthesia product expected to support Patient Care Solutions improvement in the second half of 2026. - Growth anticipated in Advanced Visualization Solutions driven by new product adoption. - China remains a cautious outlook area but shows early signs of stabilization and improvement.

- Adjusted EPS guidance for 2026 is $4.80 to $5.00 per share, representing approximately 5% to 9% growth year-over-year. - Adjusted EBIT margin for 2026 is expected to be 15.4% to 15.7%, reflecting a 10 to 40 basis point expansion year-over-year. - Free cash flow for 2026 is expected around $1.6 billion. - Inflationary pressures impacting 2026 profits (~$250 million gross impact) are partially offset by price and cost actions, with more significant pricing benefits expected in second half 2026 and 2027. - Intelerad acquisition is expected to have minimal impact on adjusted EBIT margin and EPS in 2026. - Margins and EPS expected to improve significantly in the second half of 2026. - In 2027 and beyond, expect positive bottom-line contribution and acceleration in sales growth from acquisitions and new product momentum.

- Orders grew 1.1% in the first quarter, following 10.3% growth in the year-ago period (Page 3). - Book-to-bill ratio was 1.07x for the quarter, indicating strong order intake relative to shipments (Page 3 & 5). - The backlog reached a record $21.8 billion, up $1.2 billion year-over-year (Page 3). - Capital equipment orders shown strong performance; the book-to-bill was well north of 1.1 in capital orders specifically (Page 5). - For Photon Counting CT, there is a solid funnel of opportunities over $100 million following recent approvals (Page 9). - Some monitoring deals in the Patient Care Solutions segment are more second-half loaded, expected to improve backlog conversion and sales in H2 (Page 6).